Immunotherapy

1954–1983 · 1 of 6

Monoclonal Antibody Immunotherapy

1954–1983

Monoclonal Antibody Immunotherapy

Contemporary themes

During 1954–1983, cancer immunotherapy coalesced around antibody-based targeting, with monoclonal antibodies providing predefined specificity and enabling antibody–toxin strategies across hematologic malignancies. Humoral components revealed paradoxical tumor-immune modulation, with sera blocking lymphocyte-mediated tumor rejection and antigen–antibody complexes influencing recognition. T-cell biology advanced through monoclonal antibodies delineating distinct lymphocyte subsets, while early chemoimmunotherapy and transplantation approaches demonstrated integration of immune targeting with standard therapies. Antibody–toxin conjugates showcased targeted cytotoxicity, foreshadowing future toxin-delivery strategies.

  • Antibody-based targeting and monoclonal antibodies (mAbs) became central to cancer therapy, enabling predefined specificity, targeted cytotoxicity, and antibody–toxin strategies across leukemias/lymphomas. Evidence includes continuous cultures with predefined specificity, serotherapy, and antibody conjugates.
  • Humoral components reveal paradoxical tumor-immune modulation, with sera blocking lymphocyte-mediated tumor rejection, serum factors protecting neoplastic cells, and antigen–antibody complexes influencing recognition.
  • T-cell biology and subset targeting via monoclonal antibodies advanced immune regulation research, revealing Ly antigen-defined T-cell classes, separable functional subsets, and cytotoxic/suppressor lineages with TH2 associations.
  • Combined chemoimmunotherapy and transplantation strategies extended remission in hematologic malignancies, illustrating integration of immune targeting with conventional therapies like chemotherapy and allogeneic marrow transplantation.
  • Antibody–toxin conjugates achieved targeted cytotoxicity, exemplified by ricin A chain conjugates and related toxin-delivery approaches against antigen-bearing cells.

Influential works

Hybridoma technology enabled rapid production of monoclonal antibodies, revolutionizing research, diagnostics, and the prospect of targeted immunotherapies. The development of monoclonal antibodies against activated T cells validated targeted immune interventions and opened pathways for subsequent CD-targeted therapies. Interleukin-2–driven activation of autologous lymphocytes pioneered cytokine-based adoptive immunotherapy, laying groundwork for cytokine-driven cancer treatments. The demonstration of MHC-restricted cytotoxic T cells clarified the importance of antigen presentation and T-cell–mediated responses, underpinning later T-cell–centric strategies. Collectively, these breakthroughs established a paradigm shift toward antibody- and T-cell–driven approaches in cancer immunotherapy.

  • Hybridoma technology from continuous cultures of fused cells secreting antibody of predefined specificity, revolutionizing the production of monoclonal antibodies and enabling targeted immunotherapies and diagnostics that transformed oncology and autoimmune disease research.
  • First monoclonal antibody against activated human T cells, anti-Tac; production and distribution of Tac(+) cells defined a new class of therapeutics and immunomodulatory strategies, validating monoclonal antibodies as targeted immune interventions.
  • Demonstrated Interleukin-2 (IL-2)–activated autologous lymphocytes could lyse tumor targets previously resistant to NK cells, launching cytokine-based adoptive immunotherapy and shaping IL-2–driven cancer treatments.
  • Major Histocompatibility Complex (MHC)–restricted cytotoxic T cells established the role of polymorphic MHC antigens in determining T-cell restriction, function, and responsiveness, laying the groundwork for T-cell–centric immunotherapies and vaccine approaches.
  • Characterization of the murine T cell surface molecule L3T4, identified by GK1.5, revealed parallels to human Leu-3/T4 and illuminated helper T-cell biology, informing later development of CD4-targeted therapies and T-cell immunoregulation.

1984–1996

Adoptive Immunotherapy Era

Contemporary themes

The period from 1984 to 1996 saw cancer immunotherapy coalescing around three interlocking directions. Adoptive cellular immunotherapy leveraged ex vivo–expanded lymphocytes, notably tumor-infiltrating lymphocytes, with interleukin-2 to explore autologous transfers and dosing strategies across advanced cancers. Vaccine- and dendritic-cell–centered approaches primed anti-tumor immunity through antigen presentation and cytokine-secreting tumor strategies based on granulocyte-macrophage colony-stimulating factor (GM-CSF). Monoclonal antibodies and immune-modulatory tactics shaped tumor targeting and T-cell activation by engaging costimulatory pathways via the B7/CD28/CTLA-4 axis. Costimulation and activation signals together formed a foundation for robust anti-tumor T cell responses, integrating CD8+ T cell costimulation and dendritic-cell priming. These parallel lines established core modalities and methodologies that would influence subsequent immunotherapy development.

  • Adoptive cellular immunotherapy driven by ex vivo–expanded lymphocytes (TILs/LKA) with interleukin-2, spanning autologous transfer, dosing strategies, and systemic administration across advanced cancers.
  • Vaccine- and dendritic-cell–centered approaches to prime anti-tumor immunity via antigen presentation and cytokine-secreting tumor strategies (GM-CSF), spanning irradiated tumor cell vaccines and dendritic-cell immunogenicity.
  • Monoclonal antibodies and immune-modulatory tactics enabling tumor targeting, T-cell subset manipulation, and engagement of costimulatory pathways (B7/CD28/CTLA-4) to drive tumor regression.
  • Costimulation and activation signals to shape robust anti-tumor T cell responses, integrating CD8+ T cell costimulation, B7 signaling, and dendritic-cell–driven priming.

Influential works

These pioneering efforts established core modalities for immunotherapy, setting the stage for future adoptive cell therapy, vaccine strategies, and antibody-based targeting. The emergence of checkpoint concepts through CTLA-4–related regulatory pathways forecasted the later revolution in immune modulation, while self-adjuvanting GM-CSF–secreting vaccines and IL-2–driven TIL therapy demonstrated the immunologic principles underpinning personalized and combination therapies.

  • CTLA-4 blockade paper demonstrated that inhibiting CTLA-4 unleashes T cell–mediated antitumor responses, achieving measurable tumor control in preclinical/early clinical models. It established the checkpoint blockade paradigm and directly catalyzed development of ipilimumab-like agents, shaping modern cancer immunotherapy.
  • Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF showed potent, specific, and durable antitumor immunity by turning vaccines into self-adjuvanting platforms. It popularized GM-CSF–secreting tumor vaccines and foreshadowed GM-CSF–based vaccine strategies advancing cancer immunotherapy.
  • Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma described isolating and expanding TIL from patients and administering IL-2, yielding objective responses. This work launched adoptive cell therapy with TIL, influencing subsequent ACT programs and personalized immunotherapy approaches.
  • Humanization of an anti-p185HER2 antibody for human cancer therapy described converting mouse antibody to a humanized form to reduce immunogenicity, enabling the clinical translation of anti-HER2 therapy and paving the way for trastuzumab and targeted antibody therapies in cancer.

1997–2003

Dendritic-Cell Immunotherapy

Contemporary themes

During 1997-2003, dendritic cell–driven immunotherapy emerged as a unifying framework, integrating DC-based vaccination strategies (peptide- or tumor-lysate–pulsed DCs, DC fusions, and GM-CSF–secreting DCs) to elicit broad tumor-specific T cell responses in melanoma and hematologic cancers. Rituximab-based CD20 targeting consolidated antibody-driven lymphoma therapy, while CD4+ T cells assumed a central orchestration role in shaping helper signals that govern cytotoxic responses. Antigen-specific vaccination against defined tumor antigens (gp100, Mage-3) using peptides or peptide-pulsed DCs produced durable cytotoxic responses and clinical regressions, and host–tumor immune dynamics plus adjuvants highlighted strategies to overcome immunosuppression and resistance.

  • Dendritic cell–driven vaccination and DC-based immunotherapy unify diverse approaches (peptide- or tumor lysate–pulsed DCs, DC fusions, and GM-CSF–secreting DCs) to elicit broad tumor-specific T cell responses across melanoma and hematologic cancers.
  • Antibody-based CD20 targeting with Rituximab forms a core lymphoma strategy, spanning monotherapy efficacy, multi-dose regimens, PK/PD associations, and combinations with CHOP or radioimmunotherapy.
  • CD4+ T cells emerge as central orchestrators of anti-tumor immunity, guiding helper signals that shape cytotoxic responses and overall tumor control beyond direct CD8+ effects.
  • Antigen-specific vaccination strategies target defined tumor antigens (gp100, Mage-3) via peptides or peptide-pulsed DCs to elicit durable cytotoxic T cell responses and clinical regressions.
  • Host–tumor immune conflict and adjuvant approaches highlight immunosuppression and resistance; DCs deployed as adjuvants promote immune activation and help overcome tumor resistance.

Influential works

The period established dendritic cells as master regulators of adaptive immunity and catalyzed DC-based vaccines and immunotherapy across cancers, while underpinning adjuvant approaches and foundational concepts for checkpoint biology with tumor PD-L1 expression and blockade. Early experiences with checkpoint-relevant mechanisms and DC-driven antitumor immunity laid groundwork for subsequent checkpoint inhibitors and combinatorial regimens; cytokine-based therapies such as high-dose interleukin-2 provided durable responses in select patients, guiding future cytokine use and integration with DC strategies.

  • Dendritic cells and the control of immunity (1998) positioned dendritic cells as master regulators of adaptive immunity, detailing maturation, antigen presentation, and T cell priming. This established a framework that catalyzed dendritic cell–based vaccines and immunotherapy strategies across cancer and infectious diseases.
  • Immunobiology of Dendritic Cells (2000) synthesizes dendritic cell subsets, maturation cues, cross-presentation, and immune regulation, outlining how DCs can be steered to induce immunity or tolerance. Its integrative view guided adjuvant design and DC-based therapies, fueling translational immunotherapy advances.
  • Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (2002) demonstrated tumor-expressed PD-L1 as a mechanism of immune evasion and provided a rationale for PD-1/PD-L1 checkpoint inhibitors, catalyzing a revolution in cancer immunotherapy.
  • Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (2003) showed that PD-L1/B7-H1 blockade enhances dendritic cell–driven antitumor responses, linking checkpoint inhibition with DC-based strategies and shaping subsequent combinatorial immunotherapy approaches.
  • High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 (1999) provided robust efficacy signals for IL-2–based immunotherapy, highlighting durable responses in a subset of patients and fueling ongoing exploration of cytokine therapies and combination regimens.

2004–2010

Checkpoint Blockade Immunotherapy

Contemporary themes

The period from 2004 to 2010 saw cancer immunotherapy coalescing around checkpoint blockade and regulatory T cell modulation as the dominant paradigm. Monoclonal antibodies provided versatile tools for direct tumor targeting, immune modulation, and lymphocyte depletion, while strategies to deplete, reprogram, or block recruitment of Regulatory T cells aimed to unleash durable effector CD8+ and CD4+ T cell responses. The CTLA-4 and PD-1 axes emerged as central therapeutic targets, with dose-escalation studies and early evidence of inhibitory-receptor blockade shaping clinical outcomes. Adoptive T cell approaches and chemoimmunotherapy combinations highlighted the synergy between tumor immunity and conventional cytotoxic modalities, broadening the scope of immunotherapy beyond T cells alone. The period also introduced immune-centric evaluation metrics to better capture durable, immune-driven responses and to account for pseudoprogression. Historical exploration into tumor metabolism and microenvironment began to reveal additional barriers and engineering targets for future strategies.

  • Regulatory T cell (Treg) targeting emerges as a unifying immunotherapy motif: strategies to deplete, suppress, or reprogram Tregs, or to block their recruitment, aim to unleash effector CD4+/CD8+ anti-tumor responses, integrating vaccine-, antibody-, and cell-based approaches.
  • Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) checkpoint blockade define a core immunotherapy axis: monoclonal antibodies that release inhibitory brakes on T cells, with dose-escalation studies and PD-1/PD-L1 blocking activity shaping clinical responses.
  • Monoclonal antibodies provide a versatile cancer immunotherapy platform: direct tumor targeting, immune modulation via checkpoint ligands, and lymphocyte depletion, illustrating the modularity and breadth of antibody-based strategies in oncology.
  • Adoptive T cell strategies emphasize translating high-avidity CD8+ T cell recruitment and in vitro effector programming into durable in vivo anti-tumor activity, underscoring the need to optimize function and clonal selection for clinical efficacy.
  • Chemotherapy-immunotherapy crosstalk frames a synergistic paradigm: Treg depletion by cytotoxic regimens and chemoimmunotherapy combinations converge to augment immunogenicity and responses across malignancies.

Influential works

  • Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (2009) introduced irRC, a tumor- and immune-centric endpoint that accounts for pseudoprogression and durable responses, reshaping trial design and accelerating adoption of immunotherapies.
  • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors demonstrated synergy between checkpoint inhibitors in a mouse model, providing a mechanistic foundation for human combination immunotherapies.
  • Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired revealed T cell exhaustion within the tumor microenvironment, underpinning PD-1/PD-L1 blockade as a strategy to reinvigorate anti-tumor responses.
  • Functions of natural killer cells offered a comprehensive synthesis of NK cell biology, activation pathways, and therapeutic potential, informing adoptive NK cell therapies and expanding immunotherapy beyond T cell–centric approaches.
  • Inhibitory effect of tumor cell–derived lactic acid on human T cells uncovered metabolic suppression of T cell function by tumor-produced lactic acid, highlighting metabolic barriers to immunotherapy and motivating strategies to rewire tumor metabolism.

2011–2017

Checkpoint Blockade Era

Contemporary themes

During 2011-2017, PD-1/PD-L1 and CTLA-4 blockade crystallized as a unifying paradigm across cancers, enabling durable responses and extending both monotherapy and combination strategies in melanoma, lung cancer, and hematologic malignancies. The emergence of engineered T cell therapies and autologous transfers demonstrated potent antitumor activity with lasting memory, while the pace of neoantigen discovery and tumor-immune profiling sharpened patient selection and personalization. Insights into the tumor immune microenvironment and mechanisms of resistance informed rational combinations with radiation and conventional therapies.

  • Immune checkpoint blockade using programmed cell death protein 1 (PD-1)/PD-L1 axis and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors emerged as a unifying paradigm across cancers, advancing monotherapies and combination strategies that potentiate T cell–mediated antitumor responses in melanoma, Hodgkin's lymphoma, and breast cancer.
  • Cell-based therapies based on engineered T cells—chimeric antigen receptor (CAR) T cells—and autologous T cell transfers demonstrated potent antitumor activity and durable memory in hematologic cancers, with safety and persistence profiles reported across multiple trials.
  • Neoantigen discovery and mutation-specific T cell responses underpin the rationale for immunotherapies, with tumor exome analyses revealing neoantigen-specific T-cell reactivity and mutation-targeted CD4+ T cell strategies across epithelial cancers.
  • Mechanisms of response and resistance in the tumor immune microenvironment guide rational combination strategies, including adaptive immune resistance, regulatory T cell modulation, and synergy with conventional anticancer therapies.
  • Radiation therapy can enhance immunogenicity and synergize with immune checkpoint inhibitors by engaging non-redundant immune mechanisms across tumor types.

Influential works

The period marked a turning point where immunotherapy shifted from exploratory trials to established standards of care, driven by durable responses and meaningful survival benefits across diverse malignancies. Foundational concepts—predictive biomarkers, synergy strategies, and safety management—paved the way for broader approvals and the expansion of immunotherapies beyond checkpoint inhibitors to adoptive cell therapies and neoantigen-targeted approaches.

  • "The blockade of immune checkpoints in cancer immunotherapy" introduced the immune-checkpoint blockade concept, detailing CTLA-4/PD-1 pathways and their therapeutic potential, catalyzing a decade of trials and shaping approvals across multiple cancers.
  • "Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer" demonstrated durable tumor regressions and manageable safety with PD-1 blockade across melanoma, lung, and other cancers, establishing a new cancer-immunotherapy paradigm and accelerating biomarker-driven trials.
  • "Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer" reported early activity of PD-L1 blockade across multiple cancers, confirming targetability of the PD-1/PD-L1 axis and spurring the development of PD-L1 inhibitors and combination strategies.
  • "Pembrolizumab versus Ipilimumab in Advanced Melanoma" showed pembrolizumab superior efficacy and better safety compared with ipilimumab, shifting standard-of-care to anti–PD-1 therapy and accelerating approvals across tumor types.
  • "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma" demonstrated superior response rates and survival signals with dual checkpoint blockade vs monotherapy, driving the adoption of combination regimens and guiding toxicity management.

2018–2024

Biomarker-Guided Immunotherapy

Contemporary themes

The period featured a shift toward precision immunotherapy driven by biomarker-guided patient stratification using tumor genomics, HLA class I genotyping, and antigen-presentation signatures, enabling targeted checkpoint blockade across cancers. The tumor microenvironment emerged as a central determinant of response, with TGFβ-mediated CD8+ T cell exclusion, stem-like exhausted T cells, CSF1-driven resistance, and microbiome-immune interactions collectively shaping efficacy and informing combination strategies. Additionally, dynamic states of CD8+ T cells—exhausted, stem-like, and PD-1+ pools—were recognized as predictors of response, while combination regimens and neoantigen-directed vaccines sought to broaden and sustain tumor control.

  • Biomarker-driven patient stratification using tumor genomics, HLA class I genotype, and antigen presentation signatures predicts responses to PD-1/CTLA-4 blockade, enabling targeted immunotherapy across cancers.
  • Therapy outcomes are shaped by the tumor microenvironment, including TGFβ-mediated T cell exclusion, stem-like PD-1+ CD8+ T cells, CSF1-induced resistance, and microbiome-immune interactions that collectively constrain checkpoint blockade efficacy.
  • Dynamic states of CD8+ T cells—exhausted, stem-like, and PD-1+ pools—govern tumor control and predict responsiveness to immunotherapy, underscoring the importance of intratumoral T cell differentiation trajectories.
  • Combination regimens (e.g., nivolumab+ipilimumab) extend survival and broaden efficacy by engaging complementary checkpoints and immune-modulatory pathways, illustrating multi-faceted strategies to overcome resistance.
  • Neoantigen-directed vaccines and adjuvant immune-therapy approaches aim to seed intratumoral T cell responses that synergize with checkpoint blockade to enhance tumor control.

Influential works

  • Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients showed that pre-treatment gut microbial composition strongly correlates with melanoma patients' responses to PD-1 blockade, identified taxa linked to benefit, and laid the groundwork for microbiome-targeted strategies to boost immunotherapy efficacy.
  • TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells reveals that TGFβ signaling in the tumor microenvironment creates a physical/chemical barrier that excludes CD8+ T cells, reducing PD-L1 therapy efficacy, supporting synergy with TGFβ inhibitors.
  • Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma reports durable, long-term survival benefits of dual checkpoint blockade, with sustained responses and encouraging survival curves, transforming the standard of care for advanced melanoma and guiding subsequent trials of combination immunotherapy.
  • Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic traces the emergence of TMB as a predictive biomarker for checkpoint inhibitors, defines measurement concepts, and influences patient stratification and trial design across cancers.
  • Cancer immunotherapy using checkpoint blockade provides a synthesis of checkpoint blockade mechanisms and clinical impact, framing response and resistance paradigms and guiding later work on combination strategies and biomarkers.